Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578734 · ClinicalTrials.gov registry record · Phase 2
Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old
A Phase 2 study, sponsored by Windtree Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT00578734: Completed Phase 2 study, sponsored by Windtree Therapeutics.
NCT00578734 is a Phase 2 study that has completed, run by Windtree Therapeutics. The registered enrollment target is 165 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578734, a Phase 2 study, has completed, sponsored by Windtree Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).
Primary Outcome
Duration of mechanical ventilation (MV) from baseline to successful extubation (not receiving MV for at least 24 hours) through a maximum of 14 days.
Interventions
- OTHER Sham Comparator
- DRUG Lucinactant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00578734 record still lists
NCT00578734 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% higher).
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT00578734 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00578734 about?
NCT00578734 is a clinical study titled "Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old". Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs ...
What is the current status of trial NCT00578734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2007-06. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00578734?
The interventions under investigation include: Sham Comparator (OTHER), Lucinactant (DRUG).
Who is sponsoring clinical trial NCT00578734?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00578734's enrollment target sits among peer trials
165 410th of 2000 higher than 1,588 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia